Showing results (451-460 of 470) with videos related to

Sort By:
Pageof 47
Cancer Research|November 2, 2013
OX40 is a potent immune-stimulating target in late-stage cancer patientsBrendan D Curti, Magdalena Kovacsovics-Bankowski, Nicholas Morris, et al.
The Lancet. Oncology|June 4, 2018
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialJorge Cortes, Alexander E Perl, Hartmut Döhner, et al.
Clinical and Experimental Medicine|February 8, 2023
Utility of public knowledge bases for the interpretation of comprehensive tumor molecular profiling resultsAlexandra Lebedeva, Grigory Timokhin, Ekaterina Ignatova, et al.
Biorxiv : the Preprint Server for Biology|November 19, 2025
Human brain organoids record the passage of time over multiple years in cultureIrene Faravelli, Noelia Antón-Bolaños, Anqi Wei, et al.
Cancer Research|October 23, 2012
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screeningJeffrey W Tyner, Wayne F Yang, Armand Bankhead, et al.
Annals of Hematology|November 30, 2023
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agentsJan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, et al.
Blood Advances|January 17, 2025
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALLIbrahim Aldoss, Shanpeng Li, Jianying Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 9, 2024
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Cancer Research Communications|June 25, 2025
A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 YearsEric D Eisenmann, Ronan Swords, Ying Huang, et al.
Blood Advances|July 17, 2023
Samples from patients with AML show high concordance in detection of mutations by NGS at local institutions vs central laboratoriesUma Borate, Fei Yang, Richard Press, et al.
Pageof 47